What is the patient impact?

Patient Impact of TA-GVHD

Transfusion-associated graft versus host disease (TA-GVHD) is a rare, typically fatal complication of blood transfusion with mortality estimated to be between 90–100% for those patients who develop it. Patients known to be at risk include those with congenital or acquired immunodeficiency, as well as those who receive transfusions from blood relatives, intrauterine transfusions and HLA-matched platelet transfusions. At this time there is no effective treatment for TA-GVHD.